---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-043776"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:07:45.581609+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical cuts Q1 2024 revenue guidance to $11.0-$11.3M from prior $14.8-$15.6M

## Summary
- Expected Q1 commercial revenue $11.0M-$11.3M vs prior guidance $14.8M-$15.6M.
- Full-year 2024 revenue guidance reaffirmed at lower end of $78.5M-$84.5M.
- Slower new account conversion: 73 accounts added since June 2023 vs expected 135 by March 2024.
- Launched PermeaDerm in March; RECELL GO launch upcoming.
- Q1 2024 earnings call scheduled for May 13, 2024 after market close.

## SEC filing metadata
- accession: 0000950170-24-043776
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017024043776/0000950170-24-043776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017024043776/rcel-20240410.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-043776
- JSON: https://secwatch.observer/filing/0000950170-24-043776.json
- Plain text: https://secwatch.observer/filing/0000950170-24-043776.txt

## Key facts
- Earnings Releases
  AVITA Medical, Inc. reported first quarter of 2024 results: revenue US$11.0 million to US$11.3 million. Guidance lowered.
  - Period: first quarter of 2024
  - Revenue: US$11.0 million to US$11.3 million
  - Guidance: lowered
  - Result: guidance update
  source text: previously provided guidance of US$78.5 million to US$84.5 million. For the quarter ended March 31, 2024, AVITA Medical now expects commercial revenue to be in the range of US$11.0 million to US$11.3 million. This range is below the previously provided revenue guidance of US$14.8 million to US$15.6 million. The revision in guidance is attributable to a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017024043776/0000950170-24-043776-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.